IBDEI2T9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44833,0)
 ;;=L23.9^^170^2237^2
 ;;^UTILITY(U,$J,358.3,44833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44833,1,3,0)
 ;;=3^Eczema,Allergic Contact,Unspec
 ;;^UTILITY(U,$J,358.3,44833,1,4,0)
 ;;=4^L23.9
 ;;^UTILITY(U,$J,358.3,44833,2)
 ;;=^5009125
 ;;^UTILITY(U,$J,358.3,44834,0)
 ;;=L20.82^^170^2237^3
 ;;^UTILITY(U,$J,358.3,44834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44834,1,3,0)
 ;;=3^Eczema,Flexural
 ;;^UTILITY(U,$J,358.3,44834,1,4,0)
 ;;=4^L20.82
 ;;^UTILITY(U,$J,358.3,44834,2)
 ;;=^5009109
 ;;^UTILITY(U,$J,358.3,44835,0)
 ;;=L20.84^^170^2237^4
 ;;^UTILITY(U,$J,358.3,44835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44835,1,3,0)
 ;;=3^Eczema,Intrinsic
 ;;^UTILITY(U,$J,358.3,44835,1,4,0)
 ;;=4^L20.84
 ;;^UTILITY(U,$J,358.3,44835,2)
 ;;=^5009111
 ;;^UTILITY(U,$J,358.3,44836,0)
 ;;=L51.8^^170^2237^11
 ;;^UTILITY(U,$J,358.3,44836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44836,1,3,0)
 ;;=3^Erythema Multiforme,Other
 ;;^UTILITY(U,$J,358.3,44836,1,4,0)
 ;;=4^L51.8
 ;;^UTILITY(U,$J,358.3,44836,2)
 ;;=^336639
 ;;^UTILITY(U,$J,358.3,44837,0)
 ;;=R23.4^^170^2237^15
 ;;^UTILITY(U,$J,358.3,44837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44837,1,3,0)
 ;;=3^Eschar/Desquamination of Skin
 ;;^UTILITY(U,$J,358.3,44837,1,4,0)
 ;;=4^R23.4
 ;;^UTILITY(U,$J,358.3,44837,2)
 ;;=^5019296
 ;;^UTILITY(U,$J,358.3,44838,0)
 ;;=L49.9^^170^2237^25
 ;;^UTILITY(U,$J,358.3,44838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44838,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 90% or More Body Surface
 ;;^UTILITY(U,$J,358.3,44838,1,4,0)
 ;;=4^L49.9
 ;;^UTILITY(U,$J,358.3,44838,2)
 ;;=^5009199
 ;;^UTILITY(U,$J,358.3,44839,0)
 ;;=L74.9^^170^2237^1
 ;;^UTILITY(U,$J,358.3,44839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44839,1,3,0)
 ;;=3^Eccrine Sweat Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,44839,1,4,0)
 ;;=4^L74.9
 ;;^UTILITY(U,$J,358.3,44839,2)
 ;;=^5009296
 ;;^UTILITY(U,$J,358.3,44840,0)
 ;;=L98.7^^170^2237^16
 ;;^UTILITY(U,$J,358.3,44840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44840,1,3,0)
 ;;=3^Excessive/Redundant Skin/Subq Tissue
 ;;^UTILITY(U,$J,358.3,44840,1,4,0)
 ;;=4^L98.7
 ;;^UTILITY(U,$J,358.3,44840,2)
 ;;=^5138778
 ;;^UTILITY(U,$J,358.3,44841,0)
 ;;=L72.0^^170^2237^7
 ;;^UTILITY(U,$J,358.3,44841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44841,1,3,0)
 ;;=3^Epidermal/Epidermoid Cyst
 ;;^UTILITY(U,$J,358.3,44841,1,4,0)
 ;;=4^L72.0
 ;;^UTILITY(U,$J,358.3,44841,2)
 ;;=^5009277
 ;;^UTILITY(U,$J,358.3,44842,0)
 ;;=L92.3^^170^2238^1
 ;;^UTILITY(U,$J,358.3,44842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44842,1,3,0)
 ;;=3^FB Granuloma Skin/Subcutaneous Tissue
 ;;^UTILITY(U,$J,358.3,44842,1,4,0)
 ;;=4^L92.3
 ;;^UTILITY(U,$J,358.3,44842,2)
 ;;=^5009464
 ;;^UTILITY(U,$J,358.3,44843,0)
 ;;=L66.2^^170^2238^4
 ;;^UTILITY(U,$J,358.3,44843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44843,1,3,0)
 ;;=3^Folliculitis Decalvans
 ;;^UTILITY(U,$J,358.3,44843,1,4,0)
 ;;=4^L66.2
 ;;^UTILITY(U,$J,358.3,44843,2)
 ;;=^5009254
 ;;^UTILITY(U,$J,358.3,44844,0)
 ;;=L73.9^^170^2238^3
 ;;^UTILITY(U,$J,358.3,44844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44844,1,3,0)
 ;;=3^Follicular Disorder,Superficial
 ;;^UTILITY(U,$J,358.3,44844,1,4,0)
 ;;=4^L73.9
 ;;^UTILITY(U,$J,358.3,44844,2)
 ;;=^5009286
 ;;^UTILITY(U,$J,358.3,44845,0)
 ;;=L02.221^^170^2238^5
 ;;^UTILITY(U,$J,358.3,44845,1,0)
 ;;=^358.31IA^4^2
